How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Celcuity (CELC) announced preliminary clinical data for gedatolisib in two early phase clinical trials. Gedatolisib is a multi-target inhibitor that addresses all four class I PI3K isoforms and the ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

The recommended Rexulti dosage for treating depression is 2 mg per day. However, you and your doctor will determine what dosage is best for you. The maximum recommended daily dose is 3 mg.

Alembic Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Brexpiprazole tablets used in treatment of major depressive ...

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application (ANDA) for Brexpiprazole ...

2 milligrams (mg) 5 mg; 10 mg; 15 mg; 20 mg; 30 mg; Recommended dosages. ... Abilify and Rexulti are both atypical antipsychotics used to treat major depressive disorder and schizophrenia.

The CAPS-5 total score ranks the severity of 20 PTSD symptoms from 0 (not present) to 80 (most severe). Baseline values for the combination and placebo groups, respectively, were 38.4 and 38.7 points.